galantamine hydrobromide

6H- benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-, hydrobromide 6H- benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-, hydrobromide (1:1) galanthamine bromhydrate (1:1) galanthamine HBr galanthamine hydrobromide galanthamine hydrobromide (1:1) galanthamine hydrobromide from lycoris sp. galanthamine hydrogen bromide galanthamine hydrogenbromide galanthaminehydrobromide galanthaminhydrobromid(1:1) lycoremine hydrobromide (4aS,6R,8aS)-3- methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide nivaline PubMed: Gypsogenin Derivatives: An Unexpected Class of Inhibitors of Cholinesterases. PubMed: Determination of galantamine hydrobromide in bulk drug and pharmaceutical dosage form by spectrofluorimetry. PubMed: Benzophenones from Hypericum elegans with antioxidant and acetylcholinesterase inhibitory potential. PubMed: Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors. PubMed: Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects. PubMed: Controlled release reservoir mini tablets approach for controlling the drug release of Galantamine Hydrobromide. PubMed: Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. PubMed: Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide. PubMed: The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome. PubMed: Galantamine is a novel post-exposure therapeutic against lethal VX challenge. PubMed: Bullous pemphigoid precipitated by galantamine hydrobromide. PubMed: Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. PubMed: A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. PubMed: [Criminal clozapine intoxications]. PubMed: Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers. PubMed: Cholinesterase inhibitors in the treatment of dementia. PubMed: Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products. PubMed: A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. PubMed: Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. PubMed: The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. PubMed: Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat. PubMed: The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. PubMed: Antioxidant properties of galantamine hydrobromide. PubMed: Galantamine hydrobromide: an agent for Alzheimer's disease. PubMed: Gateways to clinical trials. PubMed: Gateways to clinical trials. PubMed: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. PubMed: Gateways to Clinical Trials. June 2002. PubMed: Galantamine hydrobromide.